Empagliflozin; Linagliptin; Metformin Hydrochloride Patent Expiration
Empagliflozin; Linagliptin; Metformin Hydrochloride is used for treating Type 2 diabetes mellitus with insufficient glycemic control despite metformin therapy. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Empagliflozin; Linagliptin; Metformin Hydrochloride Patents
Given below is the list of patents protecting Empagliflozin; Linagliptin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trijardy Xr |
US9949998 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Dec 11, 2034 | Boehringer Ingelheim |
| Trijardy Xr |
US10258637 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Trijardy Xr |
US11090323 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Trijardy Xr | US9949998 | Pharmaceutical composition, methods for treating and uses thereof | Jun 11, 2034 | Boehringer Ingelheim |
| Trijardy Xr | US10258637 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Trijardy Xr | US11090323 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Trijardy Xr | US11833166 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Trijardy Xr | US10596120 | Pharmaceutical compositions | Mar 07, 2032 | Boehringer Ingelheim |
| Trijardy Xr | US11564886 | Pharmaceutical compositions | Mar 07, 2032 | Boehringer Ingelheim |
| Trijardy Xr | US10406172 | Pharmaceutical composition, methods for treating and uses thereof | Jun 15, 2030 | Boehringer Ingelheim |
| Trijardy Xr | US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | May 21, 2030 | Boehringer Ingelheim |
| Trijardy Xr |
US8551957 (Pediatric) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Apr 14, 2030 | Boehringer Ingelheim |
| Trijardy Xr | US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Oct 14, 2029 | Boehringer Ingelheim |
| Trijardy Xr | US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | Apr 02, 2029 | Boehringer Ingelheim |
| Trijardy Xr | US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | Apr 02, 2029 | Boehringer Ingelheim |
| Trijardy Xr |
US7579449 (Pediatric) | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Feb 01, 2029 | Boehringer Ingelheim |
| Trijardy Xr | US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Aug 01, 2028 | Boehringer Ingelheim |
| Trijardy Xr |
US7713938 (Pediatric) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Oct 15, 2027 | Boehringer Ingelheim |
| Trijardy Xr | US8673927 | Uses of DPP-IV inhibitors | May 04, 2027 | Boehringer Ingelheim |
| Trijardy Xr | US9173859 | Uses of DPP IV inhibitors | May 04, 2027 | Boehringer Ingelheim |
| Trijardy Xr | US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Apr 15, 2027 | Boehringer Ingelheim |
| Trijardy Xr |
US8883805 (Pediatric) | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | May 26, 2026 | Boehringer Ingelheim |
| Trijardy Xr | US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | Nov 26, 2025 | Boehringer Ingelheim |
| Trijardy Xr |
US7407955 (Pediatric) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | Nov 02, 2025 | Boehringer Ingelheim |
| Trijardy Xr | US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | May 02, 2025 | Boehringer Ingelheim |
| Trijardy Xr | US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug 12, 2023
(Expired) | Boehringer Ingelheim |
| Trijardy Xr | US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug 12, 2023
(Expired) | Boehringer Ingelheim |
| Trijardy Xr | US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun 20, 2020
(Expired) | Boehringer Ingelheim |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Empagliflozin; Linagliptin; Metformin Hydrochloride's patents.
Latest Legal Activities on Empagliflozin; Linagliptin; Metformin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Empagliflozin; Linagliptin; Metformin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2023 | US10596120 |
| Recordation of Patent Grant Mailed Critical | 31 Jan, 2023 | US11564886 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Jan, 2023 | US11564886 |
| Email Notification Critical | 12 Jan, 2023 | US11564886 |
| Issue Notification Mailed Critical | 11 Jan, 2023 | US11564886 |
| Application Is Considered Ready for Issue Critical | 27 Dec, 2022 | US11564886 |
| Dispatch to FDC | 27 Dec, 2022 | US11564886 |
| Issue Fee Payment Received Critical | 21 Dec, 2022 | US11564886 |
| Issue Fee Payment Verified Critical | 21 Dec, 2022 | US11564886 |
| Mail Notice of Allowance Critical | 27 Sep, 2022 | US11564886 |
Empagliflozin; Linagliptin; Metformin Hydrochloride's Family Patents
